Trinity Biotech (TRIB)
(Delayed Data from NSDQ)
$1.27 USD
-0.01 (-0.78%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $1.24 -0.03 (-2.36%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Trinity Biotech PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -24.02 | -41.01 | 0.88 | -6.39 | -28.91 |
Depreciation/Amortization & Depletion | 1.78 | 2.33 | 2.74 | 3.08 | 4.89 |
Net Change from Assets/Liabilities | -2.69 | -1.66 | -5.76 | -0.91 | -2.36 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 13.38 | 39.42 | 15.38 | 27.98 | 31.80 |
Net Cash From Operating Activities | -11.56 | -0.92 | 13.24 | 23.76 | 5.42 |
Property & Equipment | -0.80 | -1.10 | -1.81 | -3.21 | -2.14 |
Acquisition/ Disposition of Subsidiaries | 28.16 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -0.70 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | -1.90 | -4.88 | -6.88 | -6.99 | -9.72 |
Net Cash from Investing Activities | 24.76 | -5.98 | -8.69 | -10.20 | -11.85 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 25.40 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | -5.05 | 65.52 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -2.32 | -89.51 | 1.76 | 4.52 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -8.67 | -13.72 | -7.78 | -7.24 | -7.53 |
Net Cash from Financing Activities | -16.04 | -12.32 | -6.02 | -2.72 | -7.53 |
Effect of Exchange Rate Changes | -0.04 | -0.11 | 0.06 | 0.09 | 0.09 |
Net Change In Cash & Equivalents | -2.89 | -19.33 | -1.42 | 10.93 | -13.88 |
Cash at Beginning of Period | 6.58 | 25.91 | 27.33 | 16.40 | 30.28 |
Cash at End of Period | 3.69 | 6.58 | 25.91 | 27.33 | 16.40 |
Diluted Net EPS | -3.14 | -6.10 | 0.20 | -1.55 | -6.90 |
Fiscal Year End for Trinity Biotech PLC falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -10.07 | -3.32 | -24.02 | -18.52 | -11.80 |
Depreciation/Amortization & Depletion | 0.84 | 0.69 | 1.78 | 1.32 | 1.09 |
Net Change from Assets/Liabilities | -0.47 | -2.14 | -2.69 | -4.98 | -2.66 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 5.78 | 1.95 | 13.38 | 10.39 | 6.23 |
Net Cash From Operating Activities | -3.92 | -2.82 | -11.56 | -11.80 | -7.14 |
Property & Equipment | -0.14 | -0.07 | -0.80 | -0.55 | -0.43 |
Acquisition/ Disposition of Subsidiaries | -12.50 | -12.50 | 28.16 | 28.16 | 28.43 |
Investments | 0.00 | 0.00 | -0.70 | -0.70 | -0.70 |
Other Investing Activities | -4.49 | -1.40 | -1.90 | -1.26 | -0.77 |
Net Cash from Investing Activities | -17.13 | -13.96 | 24.76 | 25.65 | 26.53 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -0.27 | 0.00 | 0.00 | 0.00 | 0.00 |
Issuance (Repayment) of Debt | 28.18 | 21.68 | -5.05 | -5.05 | -5.05 |
Increase (Decrease) Short-Term Debt | -1.16 | -0.56 | -2.32 | -1.76 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -3.98 | -2.27 | -8.67 | -7.47 | -6.80 |
Net Cash from Financing Activities | 22.76 | 18.85 | -16.04 | -14.28 | -11.85 |
Effect of Exchange Rate Changes | -0.09 | 0.02 | -0.04 | 0.11 | 0.10 |
Net Change In Cash & Equivalents | 1.63 | 2.09 | -2.89 | -0.32 | 7.65 |
Cash at Beginning of Period | 3.69 | 3.69 | 6.58 | 6.58 | 6.58 |
Cash at End of Period | 5.32 | 5.78 | 3.69 | 6.26 | 14.23 |
Diluted Net EPS | -0.71 | -0.37 | -0.73 | -0.88 | -0.78 |